Protocol Overview
Synergy & Mechanism
Triple Synergy Mechanism
This stack targets three points on the GH axis simultaneously. CJC-1295 DAC provides a sustained GHRH baseline that elevates tonic GH secretion. Ipamorelin triggers acute GH pulses via ghrelin receptor agonism, creating the pulsatile pattern essential for fat loss and tissue repair. Tesamorelin adds additional GHRH signaling with unique visceral fat targeting proven in clinical trials.
Why Three Compounds?
The triple approach creates a more physiologic GH profile than any dual combination. CJC-1295 elevates the baseline, ipamorelin creates peaks, and tesamorelin specifically addresses visceral adiposity. Clinical data on tesamorelin (Egrifta) shows it reduces visceral fat by 15-20% independently, and this effect compounds with the other two secretagogues.
Combined Dosing Protocol
Standard
Ipa 200mcg 2x/day + CJC 2mg/wk
Tesa 2mg/day
AM/PM Ipa, weekly CJC, AM Tesa
12 weeks
Advanced
Ipa 300mcg 3x/day + CJC 2mg/wk
AM/pre-workout/PM
16 weeks
Pulse
Ipa 200mcg 2x/day (5on/2off) + CJC 2mg/wk
Tesa 2mg daily
Weekdays Ipa
Reconstitution & Preparation
Ipamorelin + CJC-1295 Preparation
Ipamorelin: 5mg vial + 2mL BAC = 2,500mcg/mL
200mcg = 8 units | 300mcg = 12 units
CJC-1295 DAC: 2mg vial + 1mL BAC = 2,000mcg/mL
2mg dose = full vial (100 units)
Tesamorelin Preparation
Tesamorelin: 2mg vials lyophilized
Reconstitute with 2mL BAC = 1,000mcg/mL
2mg dose = full vial or use larger multi-dose vial
Refrigerate all reconstituted peptides
Stacking Schedule (AM/PM Timing)
AM Protocol
Fasted AM: Tesamorelin 2mg SubQ, abdomen
30 min later: Ipamorelin 200mcg SubQ
Wait 30-60 min before eating (fasted = peak GH)
CJC-1295 DAC: once weekly (Monday)
PM Protocol
Before bed (fasted 2+ hrs): Ipamorelin 200-300mcg SubQ
Synergizes with natural nocturnal GH pulse
Do not eat after PM injection for 30+ min
Optional pre-workout dose on training days
Expected Timeline
Side Effects & Monitoring
Common Side Effects
Water retention / bloating (weeks 1-4, resolves)
Tingling in hands (carpal tunnel-like, from GH)
Increased hunger (ipamorelin, ghrelin pathway)
Joint stiffness (transient)
Injection site reactions
Precautions
Monitor IGF-1 - do not exceed 350 ng/mL
Active cancer - GH may promote growth
Diabetics: GH affects insulin sensitivity
Cycle 12 weeks on, 4 weeks off
CJC-1295 DAC may cause prolonged GH elevation
Blood Work Recommendations
GH/IGF-1
IGF-1, GH (fasted morning)
Baseline, Week 6, Week 12
Metabolic
Fasting glucose, insulin, HbA1c
Baseline, Week 8
Lipid
Cholesterol panel
Baseline, Week 12
Basic
CBC, CMP
IGF-1 is the key marker. Target range: 200-350 ng/mL. Values above 350 warrant dose reduction. Monitor fasting glucose.
Related Protocols & Tools